mitobronitol and Polycythemia-Vera

The clinical course of 16 patients with polycythemia vera (PV), treated in the period 1982 to 1993, was shown. Splenomegaly occurred in three fourths of these patients (75%), and hypertension was a major symptom. Thrombosis such as myocardial infarction and cerebral infarction was noted. Eight patients was treated with myelosuppressive agents and the 8 other patients were treated with phlebotomy. A 70-year-old male who was treated with mitobronitol (DBM) developed acute myeloblastic leukemia (AML) 11 years later. He was treated with multi-combination chemotherapy (BHAC-DMP), and entered complete remission, followed by early relapse. He became refractory to chemotherapy and died of acute pneumonia 6 months later. Median survival of 16 cases of PV was more than 10 years, and long-term treatment and care are necessary.

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hypertension; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitobronitol; Nitrosourea Compounds; Polycythemia Vera; Prognosis

Topics: Alkylating Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Hematopoietic Stem Cells; Humans; Mannitol; Mitobronitol; Pancytopenia; Polycythemia Vera

The fate of the polycythaemic patient depends on the treatment employed which may determine the nature of the transformation commonly occurring late in the course of the disease. Treatment is, on the other hand, aimed at prevention of the most frequent complications, that is of thromboembolic processes. In the last 30 years the authors treated a total of 118 PV patients, of whom 60 have died. Initially 32P treatment was applied, which was modified later, because of acute leukaemia that had occurred in 9% of the treated cases, to a single 5 mC 32P+Myelobromol (DBM) treatment. Still later only DBM was administered in the form of stosstherapy (2500 mg per day over a period of 4 days). In the latter two groups, acute leukaemia occurred as few as two cases. The course of untreated polycythaemia vera is characterized by transformation into another myeloproliferative disease. This phenomenon occurs in 50% of the cases on drastic treatment and in patients treated with 32P. Of the patients who were alive when the report was finished 35% had been free of complications, while 5.2% were suffering from chronic granulocytic leukaemia (CGL), 34.5% from sclerotic osteo-myelofibrosis (OMF-SC) and 3.4% from chronic megakaryocytic granulocytiv leukaemia (CMGL). Of the 60 patients having died, 15% had suffered from other complications being predominantly of vascular nature. 11.8% of them died of AML, 10% of CGL, 26.7% of OMF-SC and 26.7% of CMGL. The terminal stage was characterized, in the majority of cases, by blastic crisis. Based on their own results and literary data authors recommend DBM treatment besides the indispensable phlebotomy.

Topics: Adult; Aged; Aged, 80 and over; Chlorambucil; Female; Humans; Leukemia; Leukemia, Radiation-Induced; Male; Middle Aged; Mitobronitol; Phosphorus Radioisotopes; Polycythemia Vera; Primary Myelofibrosis

Topics: Aged; Follow-Up Studies; Humans; Leukemia; Mannitol; Mitobronitol; Polycythemia Vera; Risk

Topics: Humans; Leukemia; Middle Aged; Mitobronitol; Pancytopenia; Polycythemia Vera

Topics: Adult; Aged; Antineoplastic Agents; Aziridines; Busulfan; Humans; Middle Aged; Mitobronitol; Phosphorus Radioisotopes; Polycythemia Vera; Retrospective Studies; Thiazolidines

Topics: Alkylating Agents; Drug Administration Schedule; Humans; Leukemia; Mannitol; Mitobronitol; Polycythemia Vera

Topics: Adult; Aged; Drug Administration Schedule; Female; Humans; Male; Mannitol; Middle Aged; Mitobronitol; Polycythemia Vera

Topics: Autopsy; Budd-Chiari Syndrome; Humans; Intracranial Embolism and Thrombosis; Male; Middle Aged; Mitobronitol; Polycythemia Vera

Topics: Ambulatory Care; Antineoplastic Agents; Aziridines; Bloodletting; Busulfan; Drug Evaluation; Humans; Mitobronitol; Organophosphorus Compounds; Polycythemia Vera

Experience with cytostatic treatment performed in patients with polycythaemia rubra vera is reviewed. The effectivity and side effects of the drugs applied are evaluated. Mannosulfan and mitobromitol were the drugs most sutiable for treatment. In certain special cases, 5-hydroxyurea was also satisfactory, while mitolactol was the least suitable.

Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Drug Evaluation; Female; Humans; Hydroxyurea; Male; Mesylates; Middle Aged; Mitobronitol; Phosphorus Radioisotopes; Polycythemia Vera; Remission, Spontaneous